A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
Nordic consensus document on Evolut FX+ transcatheter aortic valve implantation: optimizing index implantation and longer-term outcomes
Tekijät: Khokhar, Arif A.; Savontaus, Mikko; Al-Ani, Ahmed; Terkselsen, Christian Juhl; Bieliauskas, Gintautas; van der Heijden, Annemieke; Amin Azad, Alhasan Alhaj; James, Stefan; Russell, Kristoffer; De Backer, Ole
Kustantaja: Frontiers Media SA
Julkaisuvuosi: 2025
Lehti: Frontiers in Cardiovascular Medicine
Artikkelin numero: 1682714
Vuosikerta: 12
ISSN: 2297-055X
eISSN: 2297-055X
DOI: https://doi.org/10.3389/fcvm.2025.1682714
Julkaisun avoimuus kirjaamishetkellä: Avoimesti saatavilla
Julkaisukanavan avoimuus : Kokonaan avoin julkaisukanava
Verkko-osoite: https://doi.org/10.3389/fcvm.2025.1682714
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/505621844
Transcatheter aortic valve replacement (TAVI) is an established treatment strategy for patients with severe symptomatic aortic stenosis (AS). Multiple landmark randomized controlled trials have consistently demonstrated the safety, efficacy, and longer-term durability of the CoreValve/Evolut (Medtronic, MN, USA) transcatheter aortic valve (TAV) platform in treating severe AS. These findings have supported the expansion of TAVI to younger patients with longer life expectancy, in whom an optimized index valve implantation can significantly impact both acute procedural results and longer-term outcomes. In this technical narrative, we aim to describe how iterative changes in the latest-generation Evolut FX(+) TAV can be utilized to achieve an optimized index valve implantation.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
Julkaisussa olevat rahoitustiedot:
The author(s) declare that no financial support was received for the research and/or publication of this article.
